IP Library Granted Patent US 10,898,528
Granted Patent B2
US 10,898,528 · App. 15/764,970 · Granted Jan 26, 2021

Composition comprising

Inventor: Stephen Patrick O'Hara (Yorkshire, GB)
Assignee: Optibiotix Limited
A61K35/747A61K9/19A61K35/74A61K45/06A61K47/02A61K47/12A61K47/26A61K47/36A61P9/00C12R1/25
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,898,528
App. No.
15/764,970
Granted
Jan 26, 2021
Kind
B2
Abstract

The present invention relates to compositions comprising Lactobacillus plantarum 2830 (ECGC 13110402), or mutant strain or strains thereof, for use in the treatment or prevention of hypercholesterolaemia, and in particular reducing the total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels, in an individual. Specific dosage regimes and methods of production are also claimed and described.

Claims (21)

1. A composition comprising Lactobacillus plantarum 2830, deposited at the European Collection of Cell Cultures under Accession Number 13110402, for use in the management or treatment of elevated total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels, or hypercholesterolaemia, in an individual, wherein the Lactobacillus plantarum 2830 is freeze dried and either:

(i) the composition further comprises an excipient or a carrier compound;

(ii) the composition is encapsulated; or

(iii) the Lactobacillus plantarum 2830 is concentrated.

2. The composition of claim 1 , wherein the Lactobacillus plantarum 2830 is present in an amount in the range of 1×10 5 to 1×10 12 cells.

3. The composition of claim 2 , wherein the Lactobacillus plantarum 2830 is present in an amount in the range of 1×10 8 to 1×10 10 cells.

4. The composition of claim 3 , wherein the Lactobacillus plantarum 2830 is present in an amount of about 120 mg in the composition providing about 1.8×10 9 cells.

5. The composition of claim 1 , further comprising one or more of the following: corn starch, magnesium stearate and silicon dioxide.

6. The composition of claim 1 formulated for oral administration to said individual twice daily.

7. The composition of claim 1 , wherein the composition further comprises one or more active ingredients selected from the group consisting of vitamins, minerals, phytochemicals, antioxidants, filler materials, and combinations thereof.

8. The composition of claim 7 , wherein the filler materials comprise one or more of the following: maltodextrin, sucrose or fillers with cholesterol reducing ability.

9. The composition of claim 8 , wherein the filler material comprises beta glucans.

10. The composition of claim 1 , further comprising one or more of the following: statins, sterols and/or stanols.

11. The composition of claim 1 , further comprising a prebiotic growth medium which is specific to the Lactobacillus plantarum 2830 strain.

12. The composition of claim 11 , wherein the prebiotic growth medium is capable of being produced by the Lactobacillus plantarum 2830 strain by an enzyme reaction catalyzed in reverse to produce said prebiotic growth medium.

13. The composition of claim 11 , wherein the prebiotic growth medium comprises oligosaccharides.

14. The composition of claim 13 , wherein the oligosaccharides comprise a galacto-oligosaccharide (GOS).

15. A composition comprising Lactobacillus plantarum 2830, deposited at the European Collection of Cell Cultures under Accession Number 13110402, for use in a method of treating or modulating hypercholesterolaemia in an individual, wherein the Lactobacillus plantarum 2830 is formulated for oral administration in an amount in the range of 1×10 5 to 10 12 cells once or twice a day, and wherein the Lactobacillus plantarum 2830 is in a freeze dried form, and optionally the composition further comprises one or more cholesterol lowering agents.

16. The composition of claim 15 , wherein the Lactobacillus plantarum 2830 is for administration in said individual shortly before, during or after morning and evening meals.

17. The composition of claim 16 , wherein the Lactobacillus plantarum 2830 is for administration in said individual shortly before breakfast and the evening meal.

18. The composition of claim 17 , wherein the Lactobacillus plantarum 2830 is formulated in the form of a dietary supplement.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 058240 FRAME: 0498. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Mar 9, 2022
From: OPTIBIOTIX HEALTH PLC
To: PROBIOTIX HEALTH LIMITED
Reel/Frame 059355/0988 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2021
From: OPTIBIOTIX HEALTH PLC
To: PREBIOTIX HEALTH LIMITED
Reel/Frame 058240/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2021
From: OPTIBIOTIX LIMITED
To: OPTIBIOTIX HEALTH PLC
Reel/Frame 058220/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2020
From: O'HARA, STEPHEN PATRICK
To: OPTIBIOTIX LIMITED
Reel/Frame 054660/0862 →
Priority Claims (1)
GB 1519326.1 · Nov 2, 2015 · national
Continuity (1)
Related Publication 20180318364A1 · Nov 8, 2018
Cited By (1)
US 12,673,076